Clinical Trial Update: Open Label Study to Evaluate Long Term Efficacy, Safety and Tolerability of Repeated Dosing in Subjects With Crohn's Disease and Who Participated and Successfully Completed M14-115 [Phase 3]

View source ↗

Summary

Open-label long-term extension study assessing repeated dosing in Crohn's disease patients who completed a prior Phase 3 trial; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• AbbVie

Snippet

Sponsor: AbbVie | Conditions: Crohn's Disease | Phase 3 | Status: COMPLETED | Results posted: 2018-11-14